FDA Calls on Infant Formula Industry to Strengthen Supplier Oversight

FDA Urges Increased Vigilance Across the Infant Formula Supply Chain

The U.S. Food and Drug Administration (FDA) has issued a letter to infant formula manufacturers, packagers, distributors, importers, exporters, retailers, and supply chain partners emphasizing the importance of stronger supplier oversight and ingredient risk management.

The agency’s communication follows several recent public health incidents involving infant formula products and ingredient contamination events that have prompted recalls and ongoing investigations. FDA stated that these events highlight the need for increased vigilance throughout the infant formula supply chain.

Recent Events Prompting FDA Action

According to FDA, the agency has investigated two multistate outbreaks of infant botulism associated with separate powdered infant formula products, resulting in voluntary recalls and ongoing investigations. FDA is also evaluating potential connections involving shared ingredient suppliers.

The agency additionally referenced a global contamination event involving arachidonic acid oil used in infant formula production that was linked to nearly 150 suspected and confirmed illnesses across multiple countries.

FDA noted that these incidents collectively demonstrate the importance of understanding and controlling risks associated with ingredients and suppliers throughout the manufacturing process.

FDA’s Expectations for Industry

In its letter, FDA emphasized that manufacturers should understand:

• Where ingredients originate
• How ingredients are manufactured and processed
• Potential hazards associated with ingredients
• Controls used to manage those hazards
• Risks introduced through suppliers and supply chain partners

The agency stressed that responsibility for infant formula safety extends beyond the manufacturing facility and includes every supplier and every component used in production.

Monitoring Emerging Risk Signals

FDA also encouraged manufacturers and supply chain partners to actively monitor:

• Recall notifications
• Outbreak investigations
• Import alerts
• Regulatory safety communications
• Supplier performance trends

According to FDA, these signals can provide early warning indicators of potential supply chain concerns before broader issues emerge.

What Companies Should Consider

Manufacturers of infant formula and other high-risk food products may wish to evaluate:

• Supplier qualification procedures
• Ingredient verification programs
• Supplier auditing practices
• Traceability systems
• Risk assessment processes
• Corrective action and escalation procedures
• Monitoring of regulatory and industry alerts

Companies should also ensure that supplier oversight programs remain current as ingredient sources, manufacturing practices, and global supply chains evolve.

EAS Perspective

FDA’s latest communication reinforces an important regulatory principle: food safety responsibilities extend throughout the supply chain. While infant formula manufacturers operate under some of the food industry’s most rigorous safety requirements, recent events demonstrate how vulnerabilities at the ingredient supplier level can create significant public health and business risks.

Organizations should view supplier oversight as an ongoing process rather than a one-time qualification activity. Effective supplier management programs include risk-based evaluations, verification activities, monitoring of emerging safety signals, and clear procedures for responding to potential concerns before they impact finished products.